What is HC Wainwright’s Estimate for DTIL FY2027 Earnings?

Precision BioSciences, Inc. (NASDAQ:DTIL) – Analysts at HC Wainwright boosted their FY2027 EPS estimates for Precision BioSciences in a note issued to investors on Tuesday, November 5th. HC Wainwright analyst P. Trucchio now anticipates that the company will earn $0.20 per share for the year, up from their prior estimate of $0.19. HC Wainwright currently has a “Buy” rating and a $60.00 target price on the stock. The consensus estimate for Precision BioSciences’ current full-year earnings is $0.82 per share. HC Wainwright also issued estimates for Precision BioSciences’ FY2028 earnings at $0.40 EPS.

Precision BioSciences Price Performance

DTIL opened at $8.40 on Wednesday. The firm has a market capitalization of $60.77 million, a price-to-earnings ratio of 140.00 and a beta of 1.71. Precision BioSciences has a one year low of $7.97 and a one year high of $19.43. The business has a 50 day simple moving average of $9.31 and a two-hundred day simple moving average of $10.05.

Institutional Trading of Precision BioSciences

An institutional investor recently bought a new position in Precision BioSciences stock. Janus Henderson Group PLC bought a new position in Precision BioSciences, Inc. (NASDAQ:DTIL) in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 573,052 shares of the company’s stock, valued at approximately $7,739,000. Janus Henderson Group PLC owned approximately 8.29% of Precision BioSciences as of its most recent filing with the SEC. 37.99% of the stock is owned by institutional investors.

About Precision BioSciences

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.